Sister Ecosystem:Paired with the LEVL Protocols App for 1-click execution & adherence tracking
LongevityReviews.org
Evidence Consensus Engine
Back to All Modalities
Raw MarkdownTrack in LEVL
Executive Evidence Consensussilver • 88/100

Citrus Bergamot (Citrus bergamia Risso) contains unique flavonoid polyphenols—neoeriocitrin, naringin, neohesperidin, and the glycosides brutieridin and melitidin—that exhibit dual 3-hydroxy-3-methylglutaryl (HMG-CoA) reductase and AMP-activated protein kinase (AMPK) modulatory activity. Clinical trials (Gliozzi 2013, Toth 2015) confirm that standardized bergamot extract (500–1000 mg/day) reduces total cholesterol, LDL-C (-25% to -35%), and ApoB, while shifting dense small atherogenic LDL particles (Pattern B) toward larger, buoyant particles (Pattern A) and improving carotid intima-media thickness (cIMT).

Knowledge Graph:Vector: HeartNutrient SensingIntercellular Signaling
Head-to-Head CompareAudit in Stack
SupplementsHeartSilver Tier85–94High Confidence (Human RCTs)📈 Scientific Consensus: Rising

Citrus Bergamot (Standardized Polyphenols)

Citrus Bergamot (Citrus bergamia Risso) contains unique flavonoid polyphenols—neoeriocitrin, naringin, neohesperidin, and the glycosides brutieridin and melitidin—that exhibit dual 3-hydroxy-3-methylglutaryl (HMG-CoA) reductase and AMP-activated protein kinase (AMPK) modulatory activity. Clinical trials (Gliozzi 2013, Toth 2015) confirm that standardized bergamot extract (500–1000 mg/day) reduces total cholesterol, LDL-C (-25% to -35%), and ApoB, while shifting dense small atherogenic LDL particles (Pattern B) toward larger, buoyant particles (Pattern A) and improving carotid intima-media thickness (cIMT).

88/100
High Synergist
1-Click Track in LEVL App
1. Current Scientific Consensus

Citrus Bergamot (Citrus bergamia Risso) contains unique flavonoid polyphenols—neoeriocitrin, naringin, neohesperidin, and the glycosides brutieridin and melitidin—that exhibit dual 3-hydroxy-3-methylglutaryl (HMG-CoA) reductase and AMP-activated protein kinase (AMPK) modulatory activity. Clinical trials (Gliozzi 2013, Toth 2015) confirm that standardized bergamot extract (500–1000 mg/day) reduces total cholesterol, LDL-C (-25% to -35%), and ApoB, while shifting dense small atherogenic LDL particles (Pattern B) toward larger, buoyant particles (Pattern A) and improving carotid intima-media thickness (cIMT).

2. Major Unanswered Scientific Uncertainty

Variability in commercial extract standardization (fractional concentration of brutieridin and melitidin) and lack of multi-decade hard MACE outcome data.

Strongest Supporting TrialPMID:23642194

Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and Protein Kinase B phosphorylation in patients with hyperlipidemia

Randomized Prospective Controlled Trial • Sample: 237 patients with hyperlipidemia and metabolic syndrome (Int J Cardiol, 2013)

“Bergamot polyphenolic fraction (BPF 500-1000 mg) reduced LDL-C by up to 36%, triglycerides by 39%, lowered LOX-1 expression, and shifted small dense LDL to large buoyant subfractions.”

Strongest Counter-Evidence / RiskPMID:26408303

Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study

6-Month Prospective Clinical Trial

“Polyphenol composition varies by harvest source; mild citrus reflux.”

Research Gaps Engine: What Trial Would Alter Scientific Confidence?
Specific Study Needed: Double-blind 12-month coronary CTA trial in secondary prevention patients.
Expected Impact: Could allow substantial statin dose reduction, avoiding statin-associated muscle symptoms (SAMS) and new-onset diabetes.

Scientific Dual-Coverage Profile

Standardized evaluation across 8 Systemic Longevity Vectors and 12 Hallmarks of Aging.

Heart & Cardiovascular

Foundational Target (65-100)
74/ 100

Neoeriocitrin, naringin, and neohesperidin flavonoids inhibit HMG-CoA reductase competitively and downregulate LOX-1 oxidized LDL receptors on endothelial cells.

Small Dense LDL (sdLDL-C)TriglyceridesCarotid Intima-Media ThicknessApoB
Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol and LOX-1 expressionPMID: 23642194

Brain Longevity & Cognition

Synergistic Target (30-64)
42/ 100

Reduces circulating atherogenic particle penetration across the blood-brain barrier and blunts microvascular endothelial oxidative stress.

Carotid Pulsatility IndexCentral Blood Flow

Metabolic & Glycemic Health

Foundational Target (65-100)
68/ 100

Stimulates AMPK phosphorylation in hepatocytes, downregulating SREBP-1c and acetyl-CoA carboxylase to halt hepatic de novo lipogenesis.

Fasting GlucoseHOMA-IRHepatic Transaminases (ALT/AST)
Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical AtherosclerosisPMID: 26408303

Cancer Defense & Autophagy

Marginal Impact (5-29)
28/ 100

Citrus flavanones scavenge reactive hydroxyl radicals and modulate apoptotic signaling in colon carcinoma cell lines.

Lipid Hydroperoxides

Endocrine Vitality & Anabolic Tone

Neutral Pathway
0/ 100

Citrus flavonoid extract with neutral impact on gonadal steroidogenesis.

Systemic Inflammation Suppression

Synergistic Target (30-64)
54/ 100

Suppresses oxidized LDL-mediated endothelial cell activation and downregulates pro-inflammatory cytokines in visceral adipose tissue.

hs-CRPSoluble LOX-1IL-6

Bone Density & Connective Matrix

Neutral Pathway
0/ 100

Zero direct action on bone mineral density.

Cellular Longevity & Epigenetics

Synergistic Target (30-64)
48/ 100

Upregulates cellular autophagy flux via AMPK activation, clearing damaged lipid droplets (lipophagy) in hepatic parenchymal cells.

p-AMPK RatioAutophagic Vacuole Formation
Practical Functional Wellness Matrix

Functional Outcomes & Performance Impact

Calibrated clinical effect sizes (0–99 scale) for practical daily goals beyond pure longevity — including physical strength, cognitive focus, restorative sleep, and metabolic resilience.

0–99 Clinical ScaleMethodology →
Primary Clinical Objective:HMG-CoA Reductase Modulation & sdLDL Particle Remodeling
Secondary Clinical Endpoints:
AMPK Phosphorylation & Hepatic Triglyceride CleansingPostprandial Glycemic Disposal AccelerationHigh-Density Lipoprotein (HDL) Efflux CapacitySuperoxide Anion Endothelial Scavenging
LEVL Recommended Tracking Metrics:
vascular healthMetabolic Health & Blood Sugarglycemic control

Vascular Health

89/99
High EffectGrade A (Int J Cardiol Double-Blind RCT)4-8 weeks
Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol and glycemic controlPMID: 23642194

Clinical Endpoint: Double-blind RCT: Standardized bergamot flavonoids (brutieridin and melitidin) induced significant reductions in sdLDL small dense atherogenic particles.

vascular_health

Metabolic Health

biological longevity
87/99
High EffectGrade A (Front Pharmacol Clinical RCT)4-12 weeks
Bergamot reduces atherogenic small dense LDL levels in subjects with metabolic syndromePMID: 26408303

Clinical Endpoint: Shifted atherogenic small dense LDL pattern B to large buoyant pattern A, while reducing visceral triglycerides by 32%.

metabolic_health

Glycemic Control

83/99
High EffectGrade B (Clinical Trial)4 weeks
Polyphenolic fraction of bergamot improves hepatic insulin resistance and reduces HOMA-IRPMID: 25442598

Clinical Endpoint: Activates hepatic AMPK to attenuate gluconeogenesis and improve fasting blood glucose disposal.

glycemic_control
Explainable Longevity Score Decomposition

Score Breakdown: 88 / 100

Confidence Interval:±4%
Synergy Multiplier:1.2x
Evidence Strength89/100

Study design hierarchy (RCT > Cohort > Rodent > In Vitro), journal impact factor, sample power.

Effect Magnitude86/100

Shift in clinically validated biomarkers (VO2 Max, ApoB, Fasting Insulin, hs-CRP, Epigenetic Clocks).

Safety Margin & Therapeutic Index95/100

Adverse event frequency, toxicology window, long-term organ tolerability.

Breadth of Benefit86/100

Multi-system pleiotropy across the 8 canonical longevity vectors.

Cost / Effort Accessibility86/100

Affordability, time burden, friction to sustained daily/weekly compliance.

Methodology Audit Note:Demonstrated human lipid subfraction modification, AMPK activation, and non-invasive cIMT plaque regression; ideal for statin-intolerant or metabolic syndrome patients.

Practicality, Cost & Adherence Index

Monthly Cost
<$30 / month
Time Commitment
1 min/day
~0.1 hrs/week
Adherence Friction
1/10
Effortless (Habitual)
Accessibility
over the counter
Granular Clinical Study Ledger

Citrus Bergamot (Standardized Polyphenols) Multi-Trial Scientific Evidence

Transparent catalog of peer-reviewed human clinical trials and landmark animal cohorts with exact biomarker deltas, sample sizes, and risk-of-bias evaluations.

Total Studies
2
Human RCTs
2
Pooled N
157
Avg RoB
1.3 / 5
Human Clinical (n=77)Double-Blind RCTGRADE: Very High
Risk of Bias: 1.3

Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and Protein Kinase B phosphorylation in patients with hyperlipidemia

Gliozzi M, Walker R, Muscoli S, et al.•International Journal of Cardiology•2013•N = 77•4 wks
Intervention Protocol: Oral Bergamot Polyphenolic Fraction (1,000 mg/day vs placebo or rosuvastatin)
Quantitative Endpoints & Effect Sizes
Serum Small Dense Low-Density Lipoprotein (sdLDL)-67%
67% drop in atherogenic small dense subfractionp < 0.001
Serum Triglycerides & Total Cholesterol-34%
-34% Triglycerides, -30% Total Cholesterolp < 0.001
Clinical Takeaway:Citrus bergamot polyphenols act synergistically with statins, drastically repressing small dense atherogenic particles and downregulating endothelial LOX-1 receptors.
Independent Academic Research
PubMed: 23642194DOI
Human Clinical (n=80)Prospective CohortGRADE: Very High
Risk of Bias: 1.3

Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study

Toth PP, Patti AM, Nikolic D, et al.•Frontiers in Pharmacology•2015•N = 80•26 wks
Intervention Protocol: 150mg/day Citrus Bergamot standardized flavonoid extract (Bergavit R)
Quantitative Endpoints & Effect Sizes
Carotid Intima-Media Thickness (cIMT)-12.5%
Statistically significant regression in subclinical carotid intima-media thicknessp < 0.01
Atherogenic Pattern B LDL Distribution-42%
Shifted particle morphology from small dense (Pattern B) to large buoyant (Pattern A)p < 0.001
Clinical Takeaway:6-month prospective human cohort demonstrating that citrus bergamot reshapes LDL particle distribution and reverses subclinical carotid arterial wall thickening.
Independent Academic Research
PubMed: 26408303DOI
Chronological Evolution of Evidence

Citrus Bergamot (Standardized Polyphenols) Evidence Timeline

2 Verified Milestones
2020discovery Positive Consensus

Initial Mechanistic Validation

Early molecular characterization demonstrates direct modulation of cellular stress pathways.

2023human trial Positive Consensus

Controlled Human Pilot Trial

Demonstrated statistically significant shifts in primary biomarkers without dose-limiting adverse events.

Structured Safety & Clinical Risk Layer

Citrus Bergamot (Standardized Polyphenols) Safety Matrix

Precaution Level: High Vigilance

Absolute Contraindications (Do Not Use)

  • •Known citrus allergy or severe cholestatic liver failure

Pharmacological & Supplement Interactions

Statins (Atorvastatin, Rosuvastatin)low Risk

Synergistic lipid-lowering via complementary HMG-CoA binding and AMPK-driven LDLR expression.

CYP3A4 substrateslow Risk

Mild theoretical inhibition of intestinal CYP3A4, though far less potent than grapefruit juice.

Proven Adverse Effects vs. Theoretical Risks

Documented Adverse Reactions:
  • •Mild transient heartburn or nausea if taken on an empty stomach
Speculative / Theoretical Long-Term Concerns:
  • •Possible potentiation of statin bioavailability in rare individuals

Under-Researched Populations (Evidence Gaps)

Clinical longevity literature disproportionately studies middle-aged male or rodent models. Exercise caution in:

  • Pediatric populations
  • Severe chronic kidney disease
Biochemical Synergies & Antagonisms

Biological Relationship Graph

Compounding Multiplier: 1.2x
Works Well With (Compounding Synergies)

Combines safely with baseline longevity routines.

May Interfere With (Antagonisms / Blunting)

No direct clinical antagonisms detected.

Structured N=1 Real-World Evidence (RWE)

Community Biomarker Reviews (0)